Online ISSN 2313-1519
Print    ISSN 1812-2892
Abstract - Rivaroxaban induced spontaneous hemoperitoneum around terminal ileum and cecum clinically mimicking acute appendicitis in a young patient: First case report
[PDF]           
Ibrahim Halil Inanc, Saadet Kılıc, Murat Polat

ABSTRACT

Direct oral anticoagulants have become more popular in recent years and have largely replaced vitamin K antagonists in the treatment of certain conditions, such as stroke prevention in atrial fibrillation and venous thromboembolism. Rivaroxaban is one of the direct oral anticoagulants that inhibit factor Xa and a rare cause of peritoneal haemorrhage which is uncommon and life-threatening complication. In this report, we present a 29-year-old female patient using rivaroxaban due to deep vein thrombosis after pregnancy and developing intraperitoneal hemorrhage around terminal ileum and cecum clinically mimicking acute appendicitis.

Key words: rivaroxaban, intraperitoneal hemorrhage, acute appendicitis

 

Corresponding author: Dr. Ibrahim Halil Inanc, Besni State Hospital, Department of Cardiology, Adıyaman, Turkey. Tel: +90.416 318 10 67, Fax: +90.416 318 07 73. E-mail: dr.ibrahimhalilinanc@outlook.com

 

 

References

1. Beyer-Westendorf J, Förster K, Pannach S, Ebertz F, Gelbricht V, Thieme C, et al. Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry. Blood, The Journal of the American Society of Hematology. 2014; 124(6):955-62.
https://doi.org/10.1182/blood-2014-03-563577

2. Di Minno A, Frigerio B, Spadarella G, Ravani A, Sansaro D, Amato M, et al. Old and new oral anticoagulants: food, herbal medicines and drug interactions. Blood Reviews. 2017; 31(4):193-203.
https://doi.org/10.1016/j.blre.2017.02.001

3. Mueck W, Stampfuss J, Kubitza D, Becka M. Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clinical pharmacokinetics. 2014; 53(1):1-16. https://doi.org/10.1007/s40262-013-0100-7

4. Cheung K-S, Leung WK. Gastrointestinal bleeding in patients on novel oral anticoagulants: Risk, prevention and management. World journal of gastroenterology. 2017; 23(11):1954. https://doi.org/10.3748/wjg.v23.i11.1954

5. Douxfils J, Ageno W, Samama CM, Lessire S, Ten Cate H, Verhamme P, et al. Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians. Journal of Thrombosis and Haemostasis. 2018; 16(2):209-19. https://doi.org/10.1111/jth.13912

6. Investigators E. Oral rivaroxaban for symptomatic venous thromboembolism. New England Journal of Medicine. 2010; 363(26):2499-510. https://doi.org/10.1056/NEJMoa1007903

7. Naseem Z, Mustaev M, Strekozov B. Spontaneous splenic rupture secondary to rivaroxaban: Rare but raising. IJSM. 2016; 2:134-6. https://doi.org/10.5455/ijsm.spleenrupture

8. Krause M, Henningsen A, Torge A, Juhl D, Junker R, Kenet G, et al. Impact of gender on safety and efficacy of Rivaroxaban in adolescents & young adults with venous thromboembolism. Thrombosis research. 2016; 148:145-51. https://doi.org/10.1016/j.thromres.2016.09.007

9. Sherrod BA, Condie CK, Brock AA, Ledyard H, Menacho ST, Mazur MD. Emergent Reversal of Direct Oral Anticoagulants Permitting Neurosurgical Intervention for Nonhemorrhagic Pathology. World Neurosurgery. 2020; 135:38-41. https://doi.org/10.1016/j.wneu.2019.11.162

Volume 2, Number 56 (2020)